Search results for "Gastrointestinal Tumors"

showing 10 items of 32 documents

Chemical Composition, In Vitro Antitumor and Pro-Oxidant Activities of Glandora rosmarinifolia (Boraginaceae) Essential Oil

2018

The biological properties of essential oils have been demonstrated in the treatment of several diseases and to enhance the bioavailability of other drugs. In natural habitats the essential oils compounds may play important roles in the protection of the plants as antibacterials, antivirals, antifungals, insecticides and also against herbivores by reducing their appetite for such plants or by repelling undesirable others. We analyzed by gas-chromatography mass spectrometry the chemical composition of the essential oil of aerial parts of Glandora rosmarinifolia (Ten.) D.C. Thomas obtained by hydrodistillation and verified some biological activities on a panel of hepatocellular carcinoma cell …

0301 basic medicineChemical RadicalsAntioxidantmedicine.medical_treatmentMDA-MB-231Cancer Treatmentlcsh:MedicinenaphthoquinoneChemical CompositionBiochemistryPhysical ChemistryditerpeneAntioxidantslaw.invention0302 clinical medicinelawBreast TumorsSUM 149Medicine and Health SciencesBioassaySettore BIO/15 - Biologia FarmaceuticaCytotoxicitylcsh:ScienceMultidisciplinarybiologyTraditional medicineChemistryLiver DiseasesBoraginaceaeBoraginaceaeOxidantsHep3BLipidsChemistryOncology030220 oncology & carcinogenesisPhysical SciencesResearch ArticleHepG2Free RadicalsCell SurvivalGastroenterology and HepatologyCarcinomas03 medical and health sciencesInhibitory Concentration 50Cell Line TumorAromatic HydrocarbonsGastrointestinal TumorsBreast CancermedicineOils VolatileHumansPlant OilsEssential oilcytotoxic activityHA22T/VGH; HepG2; Hep3B; SUM 149; MDA-MB-231; cytotoxic activity; diterpenes; naphthoquinones; plant secondary metabolitesVolatile Organic CompoundsDose-Response Relationship DrugCell growthPlant ExtractsHA22T/VGHlcsh:RChemical CompoundsBiology and Life SciencesCancers and NeoplasmsEpithelial CellsHepatocellular CarcinomaSettore CHIM/06 - Chimica OrganicaPlant Components Aerialbiology.organism_classificationPro-oxidantplant secondary metabolitesAntineoplastic Agents PhytogenicHydrocarbonsBioavailability030104 developmental biologySettore BIO/03 - Botanica Ambientale E ApplicataHepatocytesSettore BIO/14 - Farmacologialcsh:QOils
researchProduct

Modeling of Hepatocytes Proliferation Isolated from Proximal and Distal Zones from Human Hepatocellular Carcinoma Lesion

2016

Isolation of hepatocytes from cirrhotic human livers and subsequent primary culture are important new tools for laboratory research and cell-based therapeutics in the study of hepatocellular carcinoma (HCC). Using such techniques, we have previously identified different subpopulations of human hepatocytes and among them one is showing a progressive transformation of hepatocytes in HCC-like cells. We have hypothesized that increasing the distance from the neoplastic lesion might affect hepatocyte function and transformation capacity. However, limited information is available in comparing the growth and proliferation of human hepatocytes obtained from different areas of the same cirrhotic liv…

0301 basic medicineLiver CirrhosisMalePathologyCirrhosislcsh:MedicinePathology and Laboratory Medicine0302 clinical medicineAnimal CellsMedicine and Health SciencesTumor Cells Culturedlcsh:ScienceMultidisciplinaryLiver DiseasesFatty liverLiver NeoplasmsMiddle AgedLiverCirrhosisOncologyCell Processes030220 oncology & carcinogenesisHepatocellular carcinomaLiver FibrosisFemalemedicine.symptomCellular TypesAnatomyResearch Articlemedicine.medical_specialtyCarcinoma HepatocellularGastroenterology and HepatologyBiologyResearch and Analysis MethodsCarcinomasCell GrowthLesion03 medical and health sciencesSigns and SymptomsDiagnostic MedicineGastrointestinal TumorsmedicineCarcinomaHumansImmunohistochemistry TechniquesAgedCell ProliferationCell growthlcsh:RBiology and Life SciencesCancers and NeoplasmsCell BiologyHepatocellular Carcinomamedicine.diseaseProliferating cell nuclear antigenFatty LiverHistochemistry and Cytochemistry Techniques030104 developmental biologyCancer cellbiology.proteinHepatocytesImmunologic TechniquesLesionslcsh:QPLoS ONE
researchProduct

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro…

2018

BACKGROUND: There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician's choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC. PATIENTS AND METHODS: Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All patients were randomised to receive either avelumab 10 mg/kg by intravenous infusion every 2 weeks or physician's choice of chemotherapy (paclitaxel 80 mg/m2 on days 1, …

0301 basic medicineMaleEsophageal Neoplasmsmedicine.medical_treatmentchemotherapyGastroenterologyChoice Behaviorlaw.invention0302 clinical medicineRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointMedicinePractice Patterns Physicians'Aged 80 and overHazard ratioAntibodies MonoclonalHematologyMiddle AgedPrognosisChemotherapy regimenAdenocarcinoma MucinousSurvival RateOncology030220 oncology & carcinogenesisFemaleImmunotherapyEsophagogastric Junctionmedicine.drugPD-L1Adultmedicine.medical_specialtyAdolescentPaclitaxelAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDecision Support Techniquesgastro-oesophageal junction cancer03 medical and health sciencesYoung AdultStomach NeoplasmsInternal medicineGastrointestinal TumorsHumansddc:610Survival rateAgedChemotherapybusiness.industrygastric cancerInternational AgenciesOriginal Articlesphase IIICarcinoma PapillaryClinical trialIrinotecanEditor's Choice030104 developmental biologyavelumabNeoplasm Recurrence LocalbusinessCarcinoma Signet Ring CellBiomarkersFollow-Up Studies
researchProduct

Expression quantitative trait loci for PAX8 contributes to the prognosis of hepatocellular carcinoma

2017

Paired-box family member PAX8 encodes a transcription factor that has a role in cell differentiation and cell growth and may participate in the prognosis of hepatocellular carcinoma (HCC). By bioinformatics analysis, we identified several single nucleotide polymorphisms (SNPs) within a newly identified long non-coding RNA (lncRNA) AC016683.6 as expression quantitative trait loci (eQTLs) for PAX8. Hence, we hypothesized that PAX8eQTLs in lncRNA AC016683.6 may influence the HCC prognosis. We then performed a case-only study to assess the association between the two SNPs as well as the prognosis of HCC in 331 HBV-positive HCC patients without surgical treatment. Cox proportional hazard models …

0301 basic medicineMaleHeredityPaired BoxCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineMathematical and Statistical TechniquesMedicine and Health Scienceslcsh:ScienceMultidisciplinaryPharmaceuticsLiver DiseasesLiver NeoplasmsMiddle AgedPrognosisNucleic acidsSurvival RateGenetic MappingOncology030220 oncology & carcinogenesisHepatocellular carcinomaPhysical SciencesRegression AnalysisFemaleLiver cancerStatistics (Mathematics)Research ArticleCarcinoma HepatocellularGenotypeQuantitative Trait LociSingle-nucleotide polymorphismVariant GenotypesGastroenterology and HepatologyResearch and Analysis MethodsCarcinomasPolymorphism Single Nucleotide03 medical and health sciencesPAX8 Transcription FactorProtein DomainsDrug TherapyDiagnostic MedicineGastrointestinal TumorsCarcinomamedicineGeneticsChemotherapyHumansGenetic Predisposition to DiseaseAlleleStatistical MethodsNon-coding RNASurvival rateSurvival analysisAllelesbusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesProteinsHepatocellular Carcinomamedicine.disease030104 developmental biologyExpression quantitative trait lociCancer researchLong non-coding RNAsRNAlcsh:QbusinessMathematicsPLoS ONE
researchProduct

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or l…

2019

Abstract Background Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbations in cell polarity lead to CLDN18.2 epitopes being exposed on the cancer cell surface. The first-in-class monoclonal antibody, zolbetuximab (formerly known as IMAB362), binds to CLDN18.2 and can induce immune-mediated lysis of CLDN18.2-positive cells. Patients and methods Patients with advanced gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinomas with moderate-to-strong CLDN18.2 expression in ≥50% of tumour cells received zolbetuximab intravenously every 2 weeks for five planned infusions. At least three patients …

0301 basic medicineMalemedicine.medical_specialtyCLDN18.2Drug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsNauseagastro-oesophageal junction adenocarcinomaMedizinAdenocarcinomaGastroenterology03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineGastrointestinal TumorsmedicineHumansProgression-free survivalAgedbusiness.industryStomachgastric cancerCancerAntibodies MonoclonalHematologyOriginal ArticlesMiddle Agedmedicine.diseaseddc:IMAB362030104 developmental biologymedicine.anatomical_structureTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisCohortVomitingAdenocarcinomaFemaleEsophagogastric Junctionmedicine.symptomzolbetuximabNeoplasm Recurrence Localbusiness
researchProduct

Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer

2018

Although many anticancer agents for gastric cancer have been developed, the prognosis for many patients remains poor. Recently, costimulatory immune molecules that reactivate antitumor immune responses by utilizing the host immune system have attracted attention as new therapeutic strategies. CD137 is a costimulatory molecule that reportedly potentiates the antitumor activity of tumor-targeting monoclonal antibodies (mAbs) by enhancing antibody-dependent cellular cytotoxicity. However, it remains unclear whether CD137 stimulates tumor-regulatory activity in gastric cancer. In this study, we investigated the antitumor effects of CD137 stimulation on gastric cancer cells administered tumor-ta…

0301 basic medicinePhysiologyCytotoxicityCancer Treatmentlcsh:MedicineNK cellsToxicologyPathology and Laboratory MedicineAntineoplastic Agents ImmunologicalSpectrum Analysis Techniques0302 clinical medicineImmune PhysiologyCellular typeslcsh:ScienceInnate Immune SystemCytotoxicity AssayMultidisciplinarybiologyChemistryImmune cellsCD137Drug SynergismFlow CytometryRecombinant ProteinsUp-RegulationGene Expression Regulation NeoplasticKiller Cells NaturalOncologySpectrophotometry030220 oncology & carcinogenesisCytokinesWhite blood cellsFemaleTumor necrosis factor alphaCytophotometryAntibodyResearch ArticleCell biologyBlood cellsCell Survivalmedicine.drug_classImmunologyAntibodies Monoclonal HumanizedResearch and Analysis MethodsMonoclonal antibody03 medical and health sciencesImmune systemStomach NeoplasmsCell Line TumorGastrointestinal TumorsmedicineHumansSecretionCell ProliferationMedicine and health sciencesBiology and life scienceslcsh:RCancers and NeoplasmsCancerTrastuzumabMolecular Developmentmedicine.diseaseGranzyme BGastric Cancer4-1BB Ligand030104 developmental biologyAnimal cellsImmune SystemCancer cellCancer researchbiology.proteinlcsh:QPhysiological ProcessesDevelopmental BiologyPLOS ONE
researchProduct

Gene polymorphisms of micrornas in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancer.

2013

Background and aims MicroRNAs (miRNAs) are known for their function as translational regulators of tumor suppressor or oncogenes. Single nucleotide polymorphisms (SNPs) in miRNAs related genes have been shown to affect the regulatory capacity of miRNAs and were linked with gastric cancer (GC) and premalignant gastric conditions. The purpose of this study was to evaluate potential associations between miRNA-related gene polymorphisms (miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608) and the presence of GC or high risk atrophic gastritis (HRAG) in European population. Methods Gene polymorphisms were analyzed in 995 subjects (controls: n = 351; GC: n = 363; HRAG: n = 281) of European descen…

Bacterial DiseasesAtrophic gastritislcsh:MedicineGastroenterologyRNA interferenceGastrointestinal CancersBasic Cancer ResearchGenotypeOdds Ratiolcsh:ScienceStomach and DuodenumGeneticsMultidisciplinarybiologyInfectious DiseasesOncologyGastritisMedicineGastritismedicine.symptomResearch ArticleGastritis Atrophicmedicine.medical_specialtySingle-nucleotide polymorphismGastroenterology and HepatologyPolymorphism Single NucleotideWhite PeopleStomach NeoplasmsInternal medicineGastrointestinal TumorsGeneticsmedicineHumansAlleleBiologyHelicobacter pylorilcsh:RCancers and NeoplasmsCancerOdds ratioHelicobacter pylorimedicine.diseasebiology.organism_classificationMicroRNAsGastric CancerLogistic ModelsGenetic Polymorphismlcsh:QGene expressionPopulation GeneticsPLoS ONE
researchProduct

Chemotherapy Sensitizes Colon Cancer Initiating Cells to Vγ9Vδ2 T Cell-Mediated Cytotoxicity

2013

Colon cancer comprises a small population of cancer initiating stem cells (CIC) that is responsible for tumor maintenance and resistance to anti-cancer therapies, possibly allowing for tumor recapitulation once treatment stops. Combinations of immune-based therapies with chemotherapy and other anti-tumor agents may be of significant clinical benefit in the treatment of colon cancer. However, cellular immune-based therapies have not been experimented yet in the population of colon CICs. Here, we demonstrate that treatment with low concentrations of commonly used chemotherapeutic agents, 5- fluorouracyl and doxorubicin, sensitize colon CICs to Vc9Vd2 T cell cytotoxicity. Vc9Vd2 T cell cytotox…

Cytotoxicity ImmunologicColorectal cancermedicine.medical_treatmentCancer TreatmentGene ExpressionPharmacologyTNF-Related Apoptosis-Inducing LigandCancer immunotherapyBasic Cancer ResearchImmune Responseeducation.field_of_studyMultidisciplinaryT CellsQColon AdenocarcinomaRReceptors Antigen T-Cell gamma-deltamedicine.anatomical_structureOncologyNK Cell Lectin-Like Receptor Subfamily KColonic NeoplasmsNeoplastic Stem CellsMedicineFluorouracilImmunotherapyResearch ArticleTumor ImmunologyImmune CellsScienceT cellPrimary Cell CultureImmunologyPopulationAntineoplastic AgentsAdenocarcinomaBiologyCell LineImmune systemGastrointestinal TumorsmedicineHumanseducationBiologyImmune EvasionImmunityCancers and NeoplasmsCancerImmunotherapyImmunologic Subspecialtiesmedicine.diseaseCoculture TechniquesReceptors TNF-Related Apoptosis-Inducing LigandDoxorubicinCancer researchClinical ImmunologyT cell mediated cytotoxicityT-Lymphocytes CytotoxicDR5 c9Vd2PLoS ONE
researchProduct

Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis

2017

Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysi…

Genetics and Molecular Biology (all)0301 basic medicineLiver CirrhosisRNA virusesMaleChronic HepatitisCirrhosislcsh:MedicineAlcohol abuseHepacivirusSex FactorChronic liver diseasemedicine.disease_causeBiochemistryGastroenterologyChronic Liver Disease0302 clinical medicineRisk FactorsMedicine and Health Scienceslcsh:SciencePathology and laboratory medicineMultidisciplinaryAlcohol ConsumptionHepatitis C virusLiver DiseasesFatty livervirus diseasesHepatitis CHepatitis BMedical microbiologyMiddle AgedHepatitis BHepatitis CCirrhosisOncologyVirusesCoinfection030211 gastroenterology & hepatologyFemalePathogensResearch ArticleHumanAdultmedicine.medical_specialtyHepatitis B virusAlcohol DrinkingLiver CirrhosiGastroenterology and HepatologyMicrobiologyCarcinomas03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansNutritionAgedHepatitis B virusBiochemistry Genetics and Molecular Biology (all)Flavivirusesbusiness.industryRisk Factorlcsh:ROrganismsViral pathogensBiology and Life SciencesCancers and NeoplasmsHepatocellular Carcinomamedicine.diseaseVirologydigestive system diseasesHepatitis virusesAdult; Aged; Alcohol Drinking; Female; Hepatitis B; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)DietMicrobial pathogensFatty Liver030104 developmental biologyAgricultural and Biological Sciences (all)lcsh:Qbusiness
researchProduct

The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients.

2017

Background and aims The psychometric hepatic encephalopathy score (PHES) is the “gold standard” for minimal hepatic encephalopathy (MHE) diagnosis. Some reports suggest that some cirrhotic patients “without” MHE according to PHES show neurological deficits and other reports that neurological alterations are not homogeneous in all cirrhotic patients. This work aimed to assess whether: 1) a relevant proportion of cirrhotic patients show neurological deficits not detected by PHES; 2) cirrhotic patients with mild neurological deficits are a homogeneous population or may be classified in sub-groups according to specific deficits. Methods Cirrhotic patients “without” (n = 56) or “with” MHE (n = 4…

Liver CirrhosisMalePathologyPediatricsCirrhosisPsychometricsSocial Scienceslcsh:MedicineNeuropsychological Tests0302 clinical medicineMedicine and Health SciencesPsychologyCluster AnalysisAttentionlcsh:ScienceHepatic encephalopathyCognitive Impairmenteducation.field_of_studyMultidisciplinaryCognitive NeurologyLiver DiseasesMiddle AgedNeurologyCirrhosisOncologyFemale030211 gastroenterology & hepatologyResearch Articlemedicine.medical_specialtyPsychometricsCognitive NeurosciencePopulationGastroenterology and HepatologyCarcinomas03 medical and health sciencesNeuropsychologyGastrointestinal TumorsmedicineHumanseducationNeuropsychological TestingAgedWorking memorybusiness.industryGold standardlcsh:RCognitive PsychologyCase-control studyBiology and Life SciencesCancers and NeoplasmsReproducibility of ResultsHepatocellular Carcinomamedicine.diseasePatient Outcome AssessmentCase-Control StudiesHepatic EncephalopathyStroop TestCognitive Sciencelcsh:QbusinessPsychomotor Performance030217 neurology & neurosurgeryNeuroscienceFollow-Up StudiesStroop effectPLoS ONE
researchProduct